Álvarez BFJ, Aburto FE, Aristi UG, Chávez GG

Idioma: Español/Inglés
Referencias bibliográficas: 31
Paginas: 141-155
Archivo PDF: 478.86 Kb.

RESUMEN

El inmunofenotipo constituye un factor importante en el pronóstico del linfoma canino. Se ha demostrado que perros con linfoma de células B presentan tiempos de sobrevivencia más largos que los perros con linfoma de células T. Los antígenos CD3 y CD79a son los marcadores más utilizados en inmunohistoquímica para la determinación del fenotipo celular T y B, respectivamente, en muestras fijadas en formalina y conservadas en bloques de parafina. En este estudio se describen las características morfológicas e inmunofenotípicas de 31 casos de linfoma en México, de casos del archivo del Departamento de Patología de la Facultad de Medicina Veterinaria y Zootecnia de la Universidad Nacional Autónoma de México. Para la clasificación histológica se utilizó el sistema del National Cancer Institute-Working Formulation (NCI-WF). Catorce casos (45.16%) correspondieron a células B, 15 (48.39%) a células T, y dos (6.45%) fueron de origen indeterminado. Histopatológicamente, el linfoma difuso de células grandes fue el tipo más común, representó 38.71% de los casos; le siguieron los siguientes linfomas: linfocítico, inmunoblástico y linfoblástico. Los linfomas de grado intermedio a alto representaron 77.42% de los casos. En este estudio se encontró mayor prevalencia de linfoma de células T. Los resultados en este trabajo pudieran indicar una diferencia en la prevalencia en el inmunofenotipo del linfoma canino en México, en relación con otras zonas geográficas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. TESKE E. Canine Malignant Lymphoma: A Review and Comparisson with Human Non-Hodgkin’s Lymphoma. Vet Q 1994;16: 209-219.

2. COUTO CG. Canine Lymphomas: Something Old, Something New. Compend Cont Ed Pract Vet 1985; 7: 291-302.

3. HAHN KA, RICHARDSON RC, HAHN EA, CRISMAN CL. Diagnostic and Prognostic Importance of Chromosomal Aberrations Identified in 61 Dogs with Lymphosarcoma. Vet Pathol 1994; 31:528-540.

4. MADEWELL BR. Canine Lymphoma. Vet Clin North Am: Small Anim Prac 1985; 15: 709-722

5. GREENLEE PG, FILIPPA DA, QUIMBY FW, PATNAIK AK, CALVANO SE, MATUS RE et al. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990; 66:480-490.

6. CARTER RF, VALLI VE, LUMSDEN JH. The Cytology, Histology and Prevalence of Cell Types in Canine Lymphoma Classified According to the National Cancer Institute Working Formulation. Can J Vet Res 1986; 50:154-164.

7. MORRIS JS, DUNN JK, DOBSON JM. Canine Lymphoid Leukemia and Lymphoma with Bone Marrow Involvement: A Review of 24 Cases. J Small Anim Practice 1993; 34:72-79

8. DOBSON JM, BLACKWOOD LB, MCINNES EF, BOSTOCK DE, NICHOLLS P, HOATHER TM et al. Prognostic Variables in Canine Multicentric Lymphosarcoma. J Small Anim Pract 2001; 42: 377-384.

9. PAGE R. Canine and Feline Lymphoma: Review of Prognostic Factors and Treatment Options. 26th World Congress Proceedings of the World Small Animal Veterinary Association; 2001 August 8-11; Vancouver, British Columbia, Canada. Vancouver, British Columbia, Canada: WSAVA, 2001: 546-548.

10. RASKIN RE, FOX LE. An Interim Analysis of Geographic Differences in Morphology and Immunophenotype from 138 Cases of Canine Lymphoma. Mid-year Conference Proceedings of the 22nd Annual Conference of the Veterinary Cancer Society; 2002 April 11-14; Galena Illinois USA. Galeana Illinois USA: VCS, 2002: 11.

11. NATIONAL CANCER INSTITUTE. The Non-Hodgkin´s Lymphoma Pathologic Classification Project. National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin´s Lymphomas: Summary and Description of a Working Formulation for Clinical Usage. Cancer 1982; 49: 2112-2135.

12. RUSLANDER D, MOORE AS, GLIATTO JM, L’HEUREUX D, COTTER SM. Cytosine Arabinoside as a Single Agent for the Induction of Remission in Canine Lymphoma. J Vet Inter Med 1994; 8:299-301.

13. FERRER L, FONDEVILA D, RABANAL R, TARRES J, RAMIS A. Immunohistochemical detection of CD3 Antigen (Pan T Marker) in Canine Lymphomas. J Vet Diagn Invest 1993; 5:616-620.

14. FOURNEL-FLEURY C, MAGNOL JP, BRICAIRE P, MARCHAL T, CHABANNE B, DELVERDIER A et al. Cytohistological and Immunological Classification of Canine Malignant Lymphomas: Comparison with Human Non- Hodgkin’s Lymphomas. J Comp Path 1997; 117:35-59.

15. TESKE E, WISMAN P, MOORE PF, VAN HEERDE P. Histologic classification and immunophenotyping of canine non-Hodgkin's lymphomas: unexpected high frequency of T cell lymphomas with B cell morphology. Exp Hematol 1994; 22:1179-1187.

16. BURNETT RC, VERNAU W, MODIANO JF, OLVER CS, MOORE PF, AVERY AC. Diagnosis of Canine Lymphoid Neoplasia Using Clonal Rearrangements of Antigen Receptor Genes. Vet Pathol 2003; 40:32-41.

17. KOSAREK CE, KISSEBERTH WC, KOCIBA GJ. Use of Microarrays for Analysis of Canine Lymphoma. Proceedings of the 22nd Annual Conference of the Veterinary Cancer Society; 2002 april 11-14, Galena Illinois USA. Galeana Illinois USA: VCS, 2002:22.

18. CANIATTI M, ROCCABIANCA P, SCANZIANI E, PALTRINIERI S, MOORE PF. Canine Lymphoma: Immunocytochemical Analysis of Fine-needle Aspiration Biopsy. Vet Pathol 1996; 33:204-212.

19. FISHER DJ, NAYDAN D, WERNER LL, MOORE PF. Inmunophenotyping Lymphomas in Dogs: A Comparison of Results From Fine Needle Aspirate and Needle Biopsy Samples. Vet Clin Path 1995; 24:118-123.

20. VAIL DM, MACEWEN EG, YOUNG KM. Canine Lymphoma and Lymphoid Leukemias. In: WITHROW SJ, MACEWEN EG, editors. Small Animal Clinical Oncology. 3a ed. Philadelphia, EUA: WB Saunders Company, 2001: 558-590.

21. MILNER RJ, PEARSON J, NESBIT JW, CLOSE P. Immunophenotypic Classification of Canine Malignant Lymphoma on Formalin-Fixed Paraffin Wax-Embedded Tissue by Means of CD3 and CD79a Cell Markers. Onderstpoort J Vet Res 1996; 63:309-313.

22. VALLI VE, JACOBS RM, PARODI AL, VERNAU W, MOORE PF. Histological Classification of Hematopoietic Tumors of Domestic Animals. Washington DC, USA: Armed Forces Institute of Pathology, 2002.

23. KELLER ET. Immune-Mediated Disease as a Risk Factor for Canine Lymphoma. Cancer 1992; 70: 2334-2337.

24. DAY MJ. Immunophenotypic Characterization of Cutaneous Lymphoid Neoplasia in the Dog and Cat. J Comp Path 1995; 112: 79-96.

25. VERNAU B, MOORE P. Immunophenotyping in the Dog. Vet Cancer Soc Newsl 2001; 25:1-10.

26. KIUPEL M, TESKE E, BOSTOK D. Prognostic Factors for Treated Canine Malignant Lymphoma. Vet Pathol 1999; 36:292-300.

27. TESKE E. Prognostic Factors for Malignant Lymphoma in the Dog: an Update. Vet Q 1994;16:29-31.

28. THOMAS R, SMITH KC, GOULD R, GOWER SM, BINNS MM, BREEN M. Molecular Cytogenetic Analysis of a novel High-grade Canine T-Lymphoblastic Lymphoma Demonstrating Co-expression of CD3 and CD79a Cell Markers. Chromosome Res 2001; 9:649-657.

29. ABBAS AK, LICHTMAN AH, POBER JS. Maduración de los linfocitos B y expresión de los genes de las inmunoglobulinas. En: ABBAS AK, LICHTMAN AH, POBER JS, editores. Inmunología Celular y Molecular. 3ª ed. Madrid (España): Ed. Interamericana-McGraw Hill, 1999: 71-101.

30. VERNAU W, MOORE PF. An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction. Vet Immunol Immunopathol 1999; 69:145-164.

31. ALIZADEH AA, EISEN MB, DAVIS RE, LOSSOS IS, ROSENWALD A, BOLDRICK JC et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000: 403:503-511.